EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Indication :

Glioblastoma Multiforme


Sponsor :

Novocure GmbH


Phase :

autre


Ligne :

première


Traitement :

Optune® + RT + TMZ vs RT +TMZ


Site :

CHUV


Contact(s) :
Andreas Hottinger
Investigateur Principale

CHUV
Département d'oncologie

Rue du Bugnon 46
Lausanne
1011

0795565271
andreas.hottinger@chuv.ch

Primary objective :

To determine if TTFields treatment at 200 kHz to the brain concomitantly with RT and TMZ in the treatment of GBM patients prolongs the overall survival of patients, compared to RT and TMZ treatments followed by TTFields and maintenance TMZ